CAJ | 학술논문

制备黄芩苷缓释胶囊,并通过体外释放度对其处方进行优化.以黄芩苷为原料药,羟丙甲纤维素（HPMC）、微晶纤维素（MCC）、乳糖、聚维酮（PVP）的乙醇溶液为辅料制备缓释胶囊,考察不同因素对释放度的影响,通过正交试验优化制备处方.优化后的黄芩苷缓释胶囊的处方为黄芩苷0.5 g,HPMC 0.25 g,MCC 0.2 g,PVP的乙醇溶液浓度为6%,乳糖0.25 g.研究方法简便、快速,体外释放度显示黄芩苷缓释胶囊处方设计比较合理,可进一步研发.
제비황금감완석효낭,병통과체외석방도대기처방진행우화.이황금감위원료약,간병갑섬유소（HPMC）、미정섬유소（MCC）、유당、취유동（PVP）적을순용액위보료제비완석효낭,고찰불동인소대석방도적영향,통과정교시험우화제비처방.우화후적황금감완석효낭적처방위황금감0.5 g,HPMC 0.25 g,MCC 0.2 g,PVP적을순용액농도위6%,유당0.25 g.연구방법간편、쾌속,체외석방도현시황금감완석효낭처방설계비교합리,가진일보연발.
The prescription is optimized through evaluating the release in vitro to prepare sustained-release baicalin capsules. With baicalin for apis, hydroxyl armour cellulose (HPMC), microcrystalline cellulose (MCC), lactose, PVP ethanol solution concentration to prepare the sustained-release capsules,influence on each different factor is investigated. Using the rthogonal test method,the optimization of prescription is completed. The optimized baicalin sustained-release capsule prescription is presented : HPMC 0.25 g,baicalin 0.5 g, MCC 0.2 g, PVP ethanol solution concentration 6% ,lactose 0.25 g. This research method is simple and rapid ;the in-vitro release of baicalin also shows good rationality of the prescription design, and it can be further developed.